Last updated: 2026-09-09 09:50:00. Prices reflect the latest pre-market trading data. Stock price data is sourced from Massive.
Aldeyra Therapeutics, Inc. (ALDX) operates in the PHARMACEUTICAL PREPARATIONS sector and is listed on NASDAQ. The stock is currently priced at $1.53, with a market capitalization of $89.28M and a P/E ratio of --. Over the past 52 weeks, its price has ranged from $1.07 to $5.93. This page covers its latest market performance, valuation, price trends and company information.
$89.28M | |
$1.53 | |
$16.70 | |
$1.07 | |
$1.54 | |
1.00 | |
1.24M | |
-- | |
$5.93 | |
$1.07 | |
-- | |
-- |
Aldeyra Therapeutics, Inc. (ALDX) is trading at $1.53 in pre-market trading as of 2026-09-09 08:01:00, down 0.65% ($0.01) from the previous close of $1.54
Pre-market trading shows how investors are pricing ALDX before the regular session opens. The current pre-market price is below the previous close, indicating cautious early trading sentiment.
Over the past seven days, Aldeyra Therapeutics, Inc. (ALDX) moved from $1.49 to $1.53, representing a gain of 3.03% ($0.04).
The stock traded between $1.46 and $1.56 during the period. The latest price is near the upper end of the 7-day range, indicating moderate upward.
The average daily volume was 540.23 thousand shares, down versus the previous seven-day period, indicating lower trading activity.
Position in Range: 9.5%
ALDX is currently trading at $1.53, placing it 9.5% of the way from its 52-week low of $1.07 to its 52-week high of $5.93. This percentage reflects the stock's relative position within its 52-week trading range, not its valuation or future performance.
Aldeyra Therapeutics Inc is a biotechnology company engaged in developing and commercializing next-generation medicines to improve the lives of patients with immune-mediated and metabolic diseases. The company's product candidate, Reproxalap, is a treatment in late-stage development for dry eye disease and allergic conjunctivitis. In addition, it also has additional product candidates in development for proliferative vitreoretinopathy, primary vitreoretinal lymphoma, and other retinal diseases, autoimmune disease, and cancer. Company products includes ADX248, ADX743, ADX631, ADX246, ADX629, ADX2191.
| Industry | PHARMACEUTICAL PREPARATIONS |
| Employees | 6 |
| Exchange | NASDAQ |
| Company Website |
Eligible investors can buy real shares of Aldeyra Therapeutics, Inc. (ALDX) through MEXC RealStocks. Follow these three steps to open a RealStocks account, transfer USDT, and place a US stock order.